ANI Pharmaceuticals is building a leading Rare Disease company focused on Serving Patients, Improving Lives

RECENT NEWS

ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

2026-09-23

READ MORE >

ANI Pharmaceuticals to Present at September Investor Conferences

2026-09-03

READ MORE >

NASDAQ - ANIP

$74.43

-3.48 (-4.47%)

Pricing delayed by 20 minutes
Last updated 2026-09-23 16:00:00